Revolution Medicines Inc Forecast, price target & analysts
Revolution Medicines Inc Target price 2025 - Analyst rating & recommendation
Revolution Medicines Inc Classifications & Recommendation:
Revolution Medicines Inc Price Target
| Target Price | $72.50 |
| Price | $39.08 |
| Potential |
85.52%
register free of charge
|
| Number of Estimates | 14 |
|
14 Analysts have issued a price target Revolution Medicines Inc 2026 .
The average Revolution Medicines Inc target price is $72.50.
This is
85.52%
register free of charge
$87.00
122.62%
register free of charge
$59.00
50.97%
register free of charge
|
|
| A rating was issued by 15 analysts: 15 Analysts recommend Revolution Medicines Inc to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Revolution Medicines Inc stock has an average upside potential 2026 of
85.52%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 11.58 | 0.30 |
| 67.27% | 97.41% | |
| EBITDA Margin | -4,126.77% | -220,035.37% |
| 487.26% | 5,231.90% | |
| Net Margin | -5,591.67% | -195,672.83% |
| 282.90% | 3,399.37% |
15 Analysts have issued a sales forecast Revolution Medicines Inc 2024 . The average Revolution Medicines Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Revolution Medicines Inc EBITDA forecast 2024. The average Revolution Medicines Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Revolution Medicines Inc Analysts have issued a net profit forecast 2024. The average Revolution Medicines Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.86 | -3.50 |
| 25.32% | 9.33% | |
| P/E | negative | |
| EV/Sales | 20,251.93 |
10 Analysts have issued a Revolution Medicines Inc forecast for earnings per share. The average Revolution Medicines Inc <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Revolution Medicines Inc stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Revolution Medicines Inc...
Current Revolution Medicines Inc Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Stifel | Locked ➜ Locked | Locked | Feb 27 2025 |
| Needham | Locked ➜ Locked | Locked | Feb 27 2025 |
| UBS | Locked ➜ Locked | Locked | Jan 08 2025 |
| Wedbush | Locked ➜ Locked | Locked | Dec 06 2024 |
| Needham | Locked ➜ Locked | Locked | Dec 06 2024 |
| HC Wainwright & Co. | Locked ➜ Locked | Locked | Dec 04 2024 |
| Guggenheim | Locked ➜ Locked | Locked | Dec 03 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Stifel: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
Needham: Locked ➜ Locked
|
Feb 27 2025 |
|
Locked
UBS: Locked ➜ Locked
|
Jan 08 2025 |
|
Locked
Wedbush: Locked ➜ Locked
|
Dec 06 2024 |
|
Locked
Needham: Locked ➜ Locked
|
Dec 06 2024 |
|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Dec 04 2024 |
|
Locked
Guggenheim: Locked ➜ Locked
|
Dec 03 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
